High PSA: What to Do Next After an Elevated Result

What is PSA and what counts as a high result?

Prostate-specific antigen (PSA) is a protein produced by prostate cells, both normal and cancerous. It is measured in blood. There is no single PSA level that definitively separates cancer from no cancer. Traditionally a level above 4 ng/mL has prompted further evaluation, but this threshold is not absolute — some cancers are found below 4, and many elevated results above 4 are not cancer. Your clinician will consider your absolute PSA level, how it has changed over time (velocity), and factors like your age, prostate size, and whether you have a family history of prostate cancer 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.PSA interpretation, non-cancerous causes of PSA elevation, reflex tests, MRI use before biopsy, and risk-stratified screening recommendations2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making approach to PSA screening for men 55–69; recommendation against screening below 40 or routinely after 70.

What else can cause a high PSA besides cancer?

Many non-cancerous conditions elevate PSA:

• Benign prostatic hyperplasia (BPH): An enlarged prostate produces more PSA. In men with BPH, a PSA of 4–10 ng/mL often reflects gland size rather than malignancy.
• Prostatitis: Inflammation or infection of the prostate can transiently raise PSA significantly. If there are symptoms of prostatitis (pelvic pain, fever, painful urination), treatment and repeat testing may be the next step.
• Recent prostate manipulation: A digital rectal exam, prostate biopsy, or cystoscopy in the days prior to blood draw can elevate PSA temporarily.
• Ejaculation: Can mildly raise PSA; guidelines sometimes recommend abstaining for 24–48 hours before a PSA draw.
• Vigorous exercise: Intense cycling has been associated with PSA elevation in some studies.
• Urinary tract infection: Can cause transient elevation.

If any of these factors are present, a repeat PSA after resolution or an appropriate waiting period may be recommended before proceeding to biopsy. 3Ref 3National Cancer Institute (2023).Prostate Cancer Screening (PDQ) — Patient Version.PSA screening context: non-cancerous causes of PSA elevation (BPH, prostatitis, age), shared decision-making framework, and MRI-guided biopsy approach

What additional tests help clarify a high PSA?

Several tools help distinguish cancer from benign causes 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.PSA interpretation, non-cancerous causes of PSA elevation, reflex tests, MRI use before biopsy, and risk-stratified screening recommendations:

• Repeat PSA: A repeat draw after a few weeks, avoiding the transient factors above, confirms the result.
• PSA density: Comparing PSA to prostate volume on imaging. A large prostate that explains the PSA level is reassuring.
• Free-to-total PSA ratio: A lower proportion of free (unbound) PSA is associated with higher cancer likelihood.
• Prostate health index (PHI) and 4Kscore: Blood tests that integrate multiple PSA forms or kallikreins to estimate cancer probability more precisely.
• Multiparametric MRI (mpMRI) of the prostate: Increasingly used before biopsy to identify suspicious areas and guide needle placement, reducing unnecessary biopsies.
• Prostate biopsy: The definitive test. Done transrectally or transperineally under ultrasound or MRI guidance. Confirms or excludes cancer and, if cancer is found, determines its aggressiveness (Gleason/Grade Group).

What does the AUA recommend for PSA screening?

The AUA and its subspecialty partner (SUO) recommend a shared decision-making approach to prostate cancer screening, recognizing that PSA screening reduces prostate cancer deaths but also leads to some diagnosis and treatment of cancers that would never have caused harm 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.PSA interpretation, non-cancerous causes of PSA elevation, reflex tests, MRI use before biopsy, and risk-stratified screening recommendations. The USPSTF similarly recommends that men aged 55–69 discuss the benefits and harms of PSA screening with their clinician before deciding 2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making approach to PSA screening for men 55–69; recommendation against screening below 40 or routinely after 70. Screening is not routinely recommended below age 40 or after age 70 in men with average life expectancy. Men with a first-degree relative with prostate cancer or men of African ancestry face higher risk and may benefit from earlier discussion.

How is the biopsy decision made?

Not every elevated PSA leads to a biopsy. A urologist weighs several factors together: absolute PSA level, PSA trend over time, prostate size relative to PSA, family history, race/ethnicity (African American men have higher prostate cancer risk), any abnormality felt on rectal exam, and results of reflex tests (free/total PSA, PHI, 4Kscore, or MRI). A suspicious MRI lesion significantly raises the likelihood that a biopsy will be positive and guides exactly where to sample. An unremarkable MRI in a man with a mildly elevated PSA may support active surveillance without immediate biopsy. This is a conversation, not a formula — a urologist is the right person to guide it.